The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis

Background: Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index (PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular. Objective: This article summarizes the most important objective and subjective measurements of severity in psoriasis. For every dermatologist it is critically important to distinguish between severe psoriasis and psoriasis that severely affects QOL. Even if the PASI also has disadvantages, it is the most adequate instrument available to evaluate severity in plaque-type psoriasis. Result: We provide reasons why PASI >12 defines severe, PASI 7–12 moderate and PASI <7 mild chronic plaque-type psoriasis.

[1]  D. Luscombe,et al.  Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis , 1990, The British journal of dermatology.

[2]  James T. Elder,et al.  Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? , 2000, Journal of the American Academy of Dermatology.

[3]  S. Feldman.  A quantitative definition of severe psoriasis for use in clinical trials , 2004, The Journal of dermatological treatment.

[4]  A. Finlay,et al.  The rule of hand: 4 hand areas = 2 FTU = 1 g. , 1992, Archives of dermatology.

[5]  F. Sera,et al.  Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. , 2004, The Journal of investigative dermatology.

[6]  A. Gottlieb,et al.  The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. , 2003, Journal of drugs in dermatology : JDD.

[7]  S. Feldman,et al.  The SAPASI Is Valid and Responsive to Psoriasis Disease Severity Changes in a Multi‐Center Clinical Trial , 1999, The Journal of dermatology.

[8]  P. Gross,et al.  Genetic aspects of psoriasis. , 1957, Acta genetica et statistica medica.

[9]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[10]  R. Stern,et al.  The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. , 1997, Journal of the American Academy of Dermatology.

[11]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[12]  A. Finlay,et al.  Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis , 2003, Dermatology.

[13]  B. Elewski,et al.  Efficacy and safety of etanercept in patients with psoriasis: results of a global phase iii study , 2004 .

[14]  W. Jochum,et al.  T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.

[15]  H. Lui,et al.  The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. , 2001, Journal of the American Academy of Dermatology.

[16]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[17]  R. Chalmers,et al.  The Salford Psoriasis Index: an holistic measure of psoriasis severity , 2000, The British journal of dermatology.

[18]  S. Weisman,et al.  Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis , 2003, The Journal of dermatological treatment.

[19]  C. Main,et al.  Physical and psychologic measures are necessary to assess overall psoriasis severity. , 2001, Journal of the American Academy of Dermatology.

[20]  R. Stern,et al.  Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. , 1986, Journal of the American Academy of Dermatology.

[21]  S. Feldman,et al.  The economic impact of psoriasis increases with psoriasis severity. , 1997, Journal of the American Academy of Dermatology.

[22]  H. Williams,et al.  Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. , 2003, The Journal of investigative dermatology.

[23]  Griffiths,et al.  Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality , 1999, The British journal of dermatology.

[24]  A. Finlay,et al.  Psoriasis‐an index of disability , 1987, Clinical and experimental dermatology.

[25]  C. Main,et al.  Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. , 1997, Journal of psychosomatic research.

[26]  C. Lawrence,et al.  Measurement of involved surface area in patients with psoriasis , 1991, The British journal of dermatology.

[27]  P. C. van de Kerkhof,et al.  The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion. , 1997, The British journal of dermatology.

[28]  M. Lebwohl,et al.  An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. , 2003, Archives of dermatology.

[29]  M. Gupta,et al.  The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. , 1995, Acta dermato-venereologica.

[30]  S. Feldman,et al.  The self-administered psoriasis area and severity index is valid and reliable. , 1996, The Journal of investigative dermatology.

[31]  G. Pauli,et al.  Detection of Rare Cases of HTLV-I and -II Infections and High Numbers of HTLV-Seroindeterminate Results in Bavarian Blood Donors , 1999, Transfusion Medicine and Hemotherapy.